Y-mAbs Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Y-mAbs Therapeutics

07/11/2022 22:02

* Y-mAbs Therapeutics Inc  YMAB.OQ  reported a quarterly
adjusted
loss of 63 cents​​ per share for the quarter ended in September.
The mean expectation of nine analysts for the quarter was for a
loss of 71 cents per share.
    * Revenue rose 39.8% to $12.54 million from a year ago;
analysts
expected $12.01 million. 
    * Y-mAbs Therapeutics Inc's reported EPS for the quarter was
a
loss of 63 cents​.
    * The mean earnings estimate of analysts had fallen by
about 2.9%
in the last three months.​ 
    * In the last 30 days one analyst negatively revised an
earnings
estimate 
    * Y-mAbs Therapeutics Inc shares had fallen by 76.6% this
quarter and lost 79.2% so far this year.
    * The company reported a quarterly loss of $27.53 million.
    * Wall Street's median 12-month price target for Y-mAbs
Therapeutics Inc is $12.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 3
"hold" and 1 "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
7 at 10:02 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.71          -0.63          Beat
 Jun. 30 2022      -0.67          -0.94          Missed
 Mar. 31 2022      -0.72          -0.64          Beat
 Dec. 31 2021      -0.70          -0.85          Missed